IKZF1 Deletions in Pediatric Acute Lymphoblastic Leukemia: Still a Poor Prognostic Marker?

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2019 Dec 11

PMID 31821407

Citations 49

Authors

Martin Stanulla

Helene Cave

Anthony V Moorman

Affiliations

Soon will be listed here.

Abstract

Improved personalized adjustment of primary therapy to the perceived risk of relapse by using new prognostic markers for treatment stratification may be beneficial to patients with acute lymphoblastic leukemia (ALL). Here, we review the advances that have shed light on the role of IKZF1 aberration as prognostic factor in pediatric ALL and summarize emerging concepts in this field. Continued research on the interplay of disease biology with exposure and response to treatment will be key to further improve treatment strategies.

Citing Articles

is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort.

Krstevska Bozhinovikj E, Matevska-Geshkovska N, Staninova Stojovska M, Gjorgievska E, Jovanovska A, Kocheva S Balkan J Med Genet. 2025; 27(2):5-12.

PMID: 40070861 PMC: 11892942. DOI: 10.2478/bjmg-2024-0020.

Characterization of , and Expression in Biological Subgroups of Children with Acute Lymphoblastic Leukemia.

Lo Nigro L, Arrabito M, Andriano N, Iachelli V, La Rosa M, Bonaccorso P Int J Mol Sci. 2025; 26(3).

PMID: 39940843 PMC: 11817342. DOI: 10.3390/ijms26031076.

Real time-PCR a diagnostic tool for reporting copy number variation and relative gene-expression changes in pediatric B-cell acute lymphoblastic leukemia-a pilot study.

Sadaqat Z, Joseph S, Verma C, Muni Reddy J, Prakash A, Thomas T Biol Methods Protoc. 2025; 10(1):bpae098.

PMID: 39802454 PMC: 11717350. DOI: 10.1093/biomethods/bpae098.

Unraveling 's biofunction in human disease.

Du J, Luo H, Ye S, Zhang H, Zheng Z, Liu K Front Oncol. 2024; 14:1436576.

PMID: 39737399 PMC: 11682996. DOI: 10.3389/fonc.2024.1436576.

Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.

Ramirez Maldonado V, Navas Acosta J, Maldonado Marcos I, Villaverde Ramiro A, Hernandez-Sanchez A, Hernandez Rivas J Cancers (Basel). 2024; 16(23).

PMID: 39682152 PMC: 11639785. DOI: 10.3390/cancers16233965.

References

Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P . IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951. Leukemia. 2015; 29(11):2154-61. DOI: 10.1038/leu.2015.134. View

Qian M, Zhang H, Kham S, Liu S, Jiang C, Zhao X . Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 2016; 27(2):185-195. PMC: 5287225. DOI: 10.1101/gr.209163.116. View

Churchman M, Low J, Qu C, Paietta E, Kasper L, Chang Y . Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell. 2015; 28(3):343-56. PMC: 4573904. DOI: 10.1016/j.ccell.2015.07.016. View

van der Veer A, Waanders E, Pieters R, Willemse M, van Reijmersdal S, Russell L . Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013; 122(15):2622-9. PMC: 3795461. DOI: 10.1182/blood-2012-10-462358. View

Mullighan C, Su X, Zhang J, Radtke I, Phillips L, Miller C . Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5):470-80. PMC: 2674612. DOI: 10.1056/NEJMoa0808253. View

Rebollo A, Schmitt C . Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies. Immunol Cell Biol. 2003; 81(3):171-5. DOI: 10.1046/j.1440-1711.2003.01159.x. View

Trevino L, Yang W, French D, Hunger S, Carroll W, Devidas M . Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009; 41(9):1001-5. PMC: 2762391. DOI: 10.1038/ng.432. View

Boer J, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman H . Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia. 2015; 30(1):32-8. DOI: 10.1038/leu.2015.199. View

Yang Y, Hung C, Chen J, Lin K, Jou S, Hsiao C . IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci. 2011; 102(10):1874-81. PMC: 11159039. DOI: 10.1111/j.1349-7006.2011.02031.x. View

10.

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman M . Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016; 48(12):1481-1489. PMC: 5144107. DOI: 10.1038/ng.3691. View

11.

Zaliova M, Potuckova E, Hovorkova L, Musilova A, Winkowska L, Fiser K . deletions in childhood acute lymphoblastic leukemia with rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity. Haematologica. 2019; 104(7):1407-1416. PMC: 6601096. DOI: 10.3324/haematol.2018.204487. View

12.

Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten R . Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol. 2014; 15(3):294-304. PMC: 4494688. DOI: 10.1038/ni.2821. View

13.

Mullighan C, Miller C, Radtke I, Phillips L, Dalton J, Ma J . BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191):110-4. DOI: 10.1038/nature06866. View

14.

Hinze L, Moricke A, Zimmermann M, Junk S, Cario G, Dagdan E . Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95. Leukemia. 2017; 31(8):1840-1842. DOI: 10.1038/leu.2017.154. View

15.

Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, von Palffy S . Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016; 7:11790. PMC: 4897744. DOI: 10.1038/ncomms11790. View

16.

Chen B, Jiang L, Zhong M, Li J, Li B, Peng L . Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2017; 115(2):373-378. PMC: 5777070. DOI: 10.1073/pnas.1717125115. View

17.

Morel G, Deau M, Simand C, Caye-Eude A, Arfeuille C, Ittel A . Large deletions of the 5' region of IKZF1 lead to haploinsufficiency in B-cell precursor acute lymphoblastic leukaemia. Br J Haematol. 2019; 186(5):e155-e159. DOI: 10.1111/bjh.15994. View

18.

Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V . Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2012; 98(4):597-601. PMC: 3659991. DOI: 10.3324/haematol.2012.073965. View

19.

Chiaretti S, Gianfelici V, OBrien S, Mullighan C . Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2016; 35:e314-22. DOI: 10.1200/EDBK_156628. View

20.

Stanulla M, Dagdan E, Zaliova M, Moricke A, Palmi C, Cazzaniga G . IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2018; 36(12):1240-1249. DOI: 10.1200/JCO.2017.74.3617. View